drugset / Trial / NCT04927299

Efficacy and Safety of Losartan/Chlorthalidone vs Losartan/Hydrochlorothiazide in Essential Arterial Hypertension

NCT04927299

Phase 3 Completed 163 enrolled Laboratorios Silanes S.A. de C.V.
RandomizedParallel-groupDouble-blindTreatment

Summary

Phase IIIb, randomized, double-blind, prospective, multicenter study to evaluate the efficacy and safety of the fixed-dose combination of losartan / chlorthalidone compared with losartan / hydrochlorothiazide in the treatment of patients with essential arterial hypertension.

Timeline

Start
2022-06-30
Primary completion
2023-08-15
Completion
2023-09-11

Publications

Drugs

EvaluationDrugModalityDoseRoute
Subject Chlorthalidone Other / unclassified 12.5 mg Oral
Subject Chlorthalidone Other / unclassified 25 mg Oral
Comparator Hydrochlorothiazide Unknown 12.5 mg Oral
Comparator Hydrochlorothiazide Unknown 25 mg Oral
Subject Losartan Other / unclassified 50 mg Oral
Subject Losartan Other / unclassified 100 mg Oral